Melanoma Guidelines (Cancer Immunotherapy Guidelines-Melanoma)

The first evidence-based consensus statement on tumor immunotherapy for the treatment of patients with melanoma was released by SITC and published online by Nature Reviews Clinical Oncology in 2013.

"The Society for Immunotherapy of Cancer Consensus Statement on Tumor Immunotherapy for the Treatment of Cutaneous Melanoma," offers a road map for using immunotherapy to treat patients with melanoma. This consensus statement provides patients and physicians with expert evidence-based recommendations for the use of immunotherapies including interferon-α2, pegylated interferon, interleukin-2 (IL-2) and ipilimumab. This statement includes recommendations for patient selection, toxicity management, clinical end points, and sequencing or combination of therapies.

The Melanoma Research Foundation worked directly with SITC leadership to create an educational video about the Guidelines, published in 2013. View it below:

 

CIG Melanoma Steering Committee (CIG-Melanoma, CIG-MU)

  • Howard L. Kaufman, MD, FACS, Committee Chair – Rutgers Cancer Institute of New Jersey
  • Michael B. Atkins, MD – Georgetown-Lombardi Comprehensive Care Center
  • F. Stephen Hodi, Jr., MD – Dana-Farber Cancer Institute
  • John M. Kirkwood, MD – University of Pittsburgh

CIG-Melanoma Task Force (2011-2013)

  • Sanjiv Agarwala, MD – St. Luke´s Cancer Center
  • Thomas Amatruda, MD – Humphrey Cancer Center
  • Steven Bines, MD – Rush University Medical Center
  • Joseph I. Clark, MD – Loyola University Medical Center
  • Brendan Curti, MD – Providence Cancer Center
  • Marc Ernstoff, MD – Dartmouth-Hitchcock Medical Center
  • Thomas Gajewski, MD, PhD – University of Chicago Medical Center
  • Rene Gonzalez, MD – University of Colorado Denver
  • Patrick Hwu, MD – MD Anderson Cancer Center
  • Laura Jane Hyde – Gilda's Club
  • David Lawson, MD – Emory Winship Cancer Institute
  • Mike Lotze, MD – University of Pittsburgh
  • Jose Lutzky, MD – Mt. Sinai Comprehensive Cancer Center
  • Kim Margolin, MD – University of Washington School of Medicine
  • Dave McDermott, MD – Beth Israel Deaconess Medical Center
  • Donald Morton, MD – John Wayne Cancer Institute
  • Anna Pavlick, DO – New York University
  • Jon M. Richards, MD, PhD –Lutheran General Hospital Advanced Care Center
  • Douglas Schartzentruber, MD – Goshen Center for Cancer Care
  • Bill Sharfman, MD – Johns Hopkins University
  • Vernon Sondak, MD – H. Lee Moffitt Cancer Center and Research Institute
  • Jeff Sosman, MD – Vanderbilt-Ingram Cancer Center
  • Susan Steel – Skin of Steel (Melanoma Patient Advocacy for Chicago)
  • Ahmad Tarhini, MD – University of Pittsburgh
  • John Thompson, MD – University of Washington School of Medicine
  • Jill Titze, RN, NP Rush – University Medical Center
  • Walter Urba, MD, PhD – Providence Cancer Center
  • Richard White, Jr., MD – Carolinas Medical Center

Melanoma Guidelines Update (CIG-MU)

The CIG-Melanoma Task Force is currently updating their recommendations. All members of the 2011 – 2013 Cancer Immunotherapy Guidelines-Melanoma Steering Committee have returned to lead this important project!